[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Antipyrine.]
[J01GA01, streptomycin, Atomoxetine may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Atomoxetine may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Atomoxetine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Atomoxetine may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Atomoxetine is combined with Sulindac.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Sulpiride.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Atomoxetine is combined with Azapropazone.]
[L02BA01, tamoxifen, The metabolism of Atomoxetine can be decreased when combined with Tamoxifen.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[R03CC03, terbutaline, Atomoxetine may increase the tachycardic activities of Terbutaline.]
[B01AE07, dabigatran etexilate, Atomoxetine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Atomoxetine may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Tetrabenazine.]
[S03AA02, tetracycline, Atomoxetine may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Lurasidone.]
[A04AD10, dronabinol, The metabolism of Atomoxetine can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Apomorphine.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Atomoxetine.]
[P02CA02, thiabendazole, Atomoxetine may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Eribulin.]
[R06AD03, thiethylperazine, Atomoxetine may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[N05AB08, thioproperazine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Atomoxetine can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The metabolism of Atomoxetine can be decreased when combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Atomoxetine.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Atomoxetine is combined with Moxisylyte.]
[N05AL03, tiapride, Atomoxetine may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The metabolism of Atomoxetine can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Timolol.]
[P01AB02, tinidazole, Atomoxetine may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Atomoxetine may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Atomoxetine may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[M02AX02, tolazoline, Atomoxetine may decrease the antihypertensive activities of Tolazoline.]
[V04CA01, tolbutamide, Atomoxetine may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Atomoxetine is combined with Tolmetin.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Atomoxetine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Atomoxetine.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Atomoxetine may decrease the excretion rate of Triazolam which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Mepenzolate.]
[A16AX12, trientine, Atomoxetine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Trifluoperazine.]
[S01AD02, trifluridine, Atomoxetine may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[N05AA05, triflupromazine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Triflupromazine.]
[N04AA01, trihexyphenidyl, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Trihexyphenidyl.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Trimethadione.]
[C02BA01, trimethaphan, Atomoxetine may decrease the antihypertensive activities of Trimethaphan.]
[J01EA01, trimethoprim, Atomoxetine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Atomoxetine.]
[R06AC04, tripelennamine, The metabolism of Atomoxetine can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Triprolidine.]
[A03BB01, butylscopolamine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Butylscopolamine.]
[N06AX24, vilazodone, The metabolism of Atomoxetine can be decreased when combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, Atomoxetine may decrease the antihypertensive activities of Azilsartan medoxomil.]
[R03DX07, roflumilast, Atomoxetine may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Atomoxetine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Vandetanib.]
[R02AA14, oxyquinoline, Atomoxetine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Atomoxetine can be decreased when combined with Abiraterone.]
[J05AG05, rilpivirine, The metabolism of Atomoxetine can be decreased when combined with Rilpivirine.]
[S01AA28, vancomycin, Atomoxetine may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ezogabine.]
[B01AF01, rivaroxaban, Atomoxetine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, Atomoxetine may increase the tachycardic activities of Indacaterol.]
[C08DA01, verapamil, The metabolism of Atomoxetine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Atomoxetine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Atomoxetine can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Atomoxetine may decrease the antihypertensive activities of Vincamine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[B01AA03, warfarin, Atomoxetine may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Atomoxetine is combined with Xenon.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Zuclopenthixol.]
[L01EC01, vemurafenib, The metabolism of Atomoxetine can be decreased when combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[M05BA05, tiludronic acid, Atomoxetine may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Atomoxetine may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Crizotinib.]
[A02BC04, rabeprazole, The metabolism of Atomoxetine can be decreased when combined with Rabeprazole.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Atomoxetine may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Atomoxetine is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Atomoxetine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Tolterodine.]
[J01DH04, doripenem, Atomoxetine may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Atomoxetine may decrease the antihypertensive activities of Atenolol.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Atropine.]
[M01CB03, auranofin, Atomoxetine may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[B03XA04, peginesatide, Atomoxetine may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Atomoxetine may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Atomoxetine may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Atomoxetine may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Atomoxetine may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[A08AA11, lorcaserin, The metabolism of Atomoxetine can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The metabolism of Atomoxetine can be decreased when combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Atomoxetine can be decreased when combined with Cobicistat.]
[L02BB04, enzalutamide, Atomoxetine may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Octopamine.]
[D02BA02, octinoxate, Atomoxetine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Atomoxetine.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Atomoxetine.]
[C08CA13, lercanidipine, Atomoxetine may decrease the antihypertensive activities of Lercanidipine.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Atomoxetine.]
[N02CC03, zolmitriptan, The risk or severity of hypertension can be increased when Atomoxetine is combined with Zolmitriptan.]
[R06AC06, thonzylamine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Atomoxetine can be decreased when combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Atomoxetine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of hypertension can be increased when Atomoxetine is combined with Diethyl ether.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Atomoxetine can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Atomoxetine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Atomoxetine.]
[A16AX08, teduglutide, Atomoxetine may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Bencyclane.]
[A10BH04, alogliptin, Atomoxetine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Atomoxetine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Atomoxetine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[G03XC05, ospemifene, The metabolism of Atomoxetine can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Atomoxetine is combined with Benorilate.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Atomoxetine can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Atomoxetine.]
[L03AA12, ancestim, Atomoxetine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Atomoxetine can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Atomoxetine is combined with Naratriptan.]
[L04AA18, everolimus, The metabolism of Atomoxetine can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Atomoxetine.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Benzydamine.]
[L01EE01, trametinib, Atomoxetine may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Atomoxetine.]
[V09AX05, florbetapir F-18, Atomoxetine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, Atomoxetine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C08EA02, bepridil, The metabolism of Atomoxetine can be decreased when combined with Bepridil.]
[C02KX05, riociguat, Atomoxetine may decrease the antihypertensive activities of Riociguat.]
[A10BJ03, lixisenatide, Atomoxetine may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Atomoxetine may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Atomoxetine.]
[N06AX26, vortioxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Vortioxetine.]
[G03AC08, etonogestrel, Atomoxetine may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[J05AP08, sofosbuvir, Atomoxetine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Atomoxetine may increase the tachycardic activities of Droxidopa.]
[C07AB04, acebutolol, The metabolism of Atomoxetine can be decreased when combined with Acebutolol.]
[N05CH03, tasimelteon, Atomoxetine may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, The metabolism of Atomoxetine can be increased when combined with Apremilast.]
[L02BG02, formestane, Atomoxetine may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S01ED02, betaxolol, Atomoxetine may decrease the antihypertensive activities of Betaxolol.]
[V03AB34, fomepizole, Atomoxetine may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, Atomoxetine may decrease the antihypertensive activities of Bethanidine.]
[L04AC11, siltuximab, The metabolism of Atomoxetine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Hyoscyamine.]
[R03AC19, olodaterol, Atomoxetine may increase the tachycardic activities of Olodaterol.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[D11AA01, glycopyrronium, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[A16AX10, eliglustat, The metabolism of Atomoxetine can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Atomoxetine can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Acepromazine.]
[N04AA02, biperiden, The metabolism of Atomoxetine can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Atomoxetine.]
[S03AA06, gentamicin, Atomoxetine may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Atomoxetine.]
[B01AF03, edoxaban, Atomoxetine may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Atomoxetine can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Atomoxetine can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, Atomoxetine may decrease the excretion rate of Acetaminophen which could result in a higher serum level.]
[L01DC01, bleomycin, Atomoxetine may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[A03AA09, difemerine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Difemerine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Atomoxetine can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The risk or severity of hypertension can be increased when Atomoxetine is combined with Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Atomoxetine can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of hypertension can be increased when Atomoxetine is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Atomoxetine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Atomoxetine is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC03, lansoprazole, The metabolism of Atomoxetine can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Atomoxetine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Atomoxetine.]
[J02AC05, isavuconazole, The metabolism of Atomoxetine can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Atomoxetine.]
[L01XG03, ixazomib, Atomoxetine may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, Atomoxetine may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Alfuzosin.]
[M04AB05, lesinurad, Atomoxetine may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Atomoxetine is combined with Alminoprofen.]
[N03AX23, brivaracetam, Atomoxetine may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[N05BA08, bromazepam, Atomoxetine may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Atomoxetine may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dexbrompheniramine.]
[N06AA19, amineptin, The risk or severity of hypertension can be increased when Atomoxetine is combined with Amineptine.]
[C08CA01, amlodipine, Atomoxetine may decrease the antihypertensive activities of Amlodipine.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, Atomoxetine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Atomoxetine can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Buserelin.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Atomoxetine is combined with Buspirone.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Artemether.]
[M02AA03, clofezone, The metabolism of Atomoxetine can be decreased when combined with Rabeprazole.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Azatadine.]
[S01GX07, azelastine, The metabolism of Atomoxetine can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Atomoxetine can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Azithromycin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Atomoxetine is combined with Balsalazide.]
[R03CC12, bambuterol, Atomoxetine may increase the tachycardic activities of Bambuterol.]
[A06AH05, naldemedine, Atomoxetine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Atomoxetine.]
[C09AA07, benazepril, Atomoxetine may decrease the antihypertensive activities of Benazepril.]
[P01CA02, benznidazole, Atomoxetine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Atomoxetine.]
[J05AF06, abacavir, Atomoxetine may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Atomoxetine can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Atomoxetine may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Atomoxetine can be increased when combined with Infliximab.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Safinamide is combined with Atomoxetine.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Delafloxacin.]
[L01BC06, capecitabine, Atomoxetine may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Atomoxetine can be decreased when combined with Enasidenib.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Vorinostat.]
[C07AB07, bisoprolol, Atomoxetine may decrease the antihypertensive activities of Bisoprolol.]
[R03AC17, bitolterol, Atomoxetine may increase the tachycardic activities of Bitolterol.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Atomoxetine.]
[N04AA11, bornaprine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Bornaprine.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Atomoxetine may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Atomoxetine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Atomoxetine is combined with Bumadizone.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Atomoxetine.]
[N06AA15, butriptyline, The risk or severity of hypertension can be increased when Atomoxetine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Acetyldigoxin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Acrivastine.]
[C09AA01, captopril, Atomoxetine may decrease the antihypertensive activities of Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Macimorelin.]
[L02BB05, apalutamide, Atomoxetine may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Atomoxetine may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A03AA03, camylofine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Carbinoxamine.]
[C07AG02, carvedilol, Atomoxetine may decrease the antihypertensive activities of Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Atomoxetine can be decreased when combined with Cannabidiol.]
[L04AA37, baricitinib, Atomoxetine may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Encorafenib.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01GB14, plazomicin, Atomoxetine may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Atomoxetine may increase the tachycardic activities of Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Atomoxetine.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Atomoxetine.]
[A16AX14, migalastat, Atomoxetine may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Atomoxetine can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Atomoxetine can be decreased when combined with Dacomitinib.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Cetirizine.]
[D08AE05, chloroxylenol, Atomoxetine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Atomoxetine is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Inotersen.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Atomoxetine.]
[L04AA39, emapalumab, The metabolism of Atomoxetine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Amifampridine.]
[A06AX05, prucalopride, Atomoxetine may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Cibenzoline.]
[C09AA08, cilazapril, Atomoxetine may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Atomoxetine is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Atomoxetine can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Atomoxetine.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Atomoxetine is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Atomoxetine.]
[N05BA09, clobazam, The metabolism of Atomoxetine can be decreased when combined with Clobazam.]
[C09CA06, candesartan, Atomoxetine may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Atomoxetine can be increased when combined with Etanercept.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[L01EJ02, fedratinib, The metabolism of Atomoxetine can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Entrectinib.]
[N07XX11, pitolisant, The metabolism of Atomoxetine can be decreased when combined with Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Atomoxetine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Atomoxetine.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Yohimbine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[A16AX16, givosiran, The serum concentration of Atomoxetine can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Atomoxetine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, The metabolism of Atomoxetine can be decreased when combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Atomoxetine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[M01AX21, diacetylrhein, The metabolism of Atomoxetine can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Atomoxetine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Atomoxetine.]
[N02CC07, frovatriptan, The risk or severity of hypertension can be increased when Atomoxetine is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Atomoxetine is combined with Dutasteride.]
[R02AA03, dichlorobenzyl alcohol, Atomoxetine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Atomoxetine may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Atomoxetine.]
[N02CC06, eletriptan, The risk or severity of hypertension can be increased when Eletriptan is combined with Atomoxetine.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Atomoxetine is combined with Rofecoxib.]
[C08CA16, clevidipine, Atomoxetine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The metabolism of Atomoxetine can be decreased when combined with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Chlorcyclizine.]
[C02AA06, methoserpidine, Atomoxetine may decrease the antihypertensive activities of Methoserpidine.]
[A03AA08, dihexyverine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Dopexamine.]
[G04BD09, trospium, The metabolism of Atomoxetine can be decreased when combined with Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Atomoxetine is combined with Droxicam.]
[V08CA05, mangafodipir, Atomoxetine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Atomoxetine is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Atomoxetine is combined with Dexketoprofen.]
[C08CA17, levamlodipine, Atomoxetine may decrease the antihypertensive activities of Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Atomoxetine can be decreased when combined with Proguanil.]
[N02AX07, oliceridine, The metabolism of Oliceridine can be decreased when combined with Atomoxetine.]
[P01BA01, chloroquine, The metabolism of Atomoxetine can be decreased when combined with Chloroquine.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The metabolism of Atomoxetine can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Atomoxetine can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, Atomoxetine may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Atomoxetine may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[A11CC05, cholecalciferol, The metabolism of Atomoxetine can be decreased when combined with Cholecalciferol.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Atomoxetine is combined with Ethenzamide.]
[N02BA03, choline salicylate, Atomoxetine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Atomoxetine is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Atomoxetine is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Atomoxetine can be decreased when combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Atomoxetine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Atomoxetine is combined with Naxitamab.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Atomoxetine is combined with Fenbufen.]
[C01CA19, fenoldopam, Atomoxetine may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Atomoxetine is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Atomoxetine is combined with Finasteride.]
[J01DD15, cefdinir, Atomoxetine may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Flumequine.]
[N02BG07, flupirtine, Atomoxetine may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, Atomoxetine may increase the tachycardic activities of Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Atomoxetine.]
[N01AB05, trichloroethylene, The risk or severity of hypertension can be increased when Atomoxetine is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Atomoxetine can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Atomoxetine may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Atomoxetine can be decreased when combined with Cimetidine.]
[V08CA04, gadoteridol, Atomoxetine may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ciprofloxacin.]
[L01XA01, cisplatin, Atomoxetine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The metabolism of Atomoxetine can be decreased when combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Atomoxetine is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Atomoxetine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Atomoxetine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Atomoxetine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The metabolism of Atomoxetine can be decreased when combined with Clemastine.]
[R03CC13, clenbuterol, Atomoxetine may increase the tachycardic activities of Clenbuterol.]
[N06AX25, St. John's wort extract, The metabolism of Atomoxetine can be decreased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Atomoxetine can be decreased when combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Clofazimine.]
[N01BB10, levobupivacaine, Atomoxetine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Atomoxetine can be decreased when combined with Clomipramine.]
[N03AE01, clonazepam, Atomoxetine may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Atomoxetine.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Granisetron.]
[L01XX77, adagrasib, The serum concentration of Atomoxetine can be increased when it is combined with Adagrasib.]
[N05AH02, clozapine, The metabolism of Atomoxetine can be decreased when combined with Clozapine.]
[J01GB12, arbekacin, Atomoxetine may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The metabolism of Atomoxetine can be decreased when combined with Cocaine.]
[C02KB01, metyrosine, Atomoxetine may decrease the antihypertensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Atomoxetine can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Atomoxetine is combined with Proquazone.]
[R05DA04, codeine, The metabolism of Codeine can be decreased when combined with Atomoxetine.]
[M04AC01, colchicine, Atomoxetine may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Homatropine methylbromide.]
[J01XB01, colistin, Atomoxetine may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Desflurane.]
[A04AA03, tropisetron, Atomoxetine may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, The risk or severity of hypertension can be increased when Atomoxetine is combined with Ifenprodil.]
[A10BX03, nateglinide, Atomoxetine may decrease the excretion rate of Nateglinide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Atomoxetine is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Atomoxetine.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Atomoxetine is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Desloratadine.]
[J05AB14, valganciclovir, Atomoxetine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Atomoxetine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Atomoxetine may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Atomoxetine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Atomoxetine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Atomoxetine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Atomoxetine is combined with Valdecoxib.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Atomoxetine is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of hypertension can be increased when Atomoxetine is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Atomoxetine is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Itraconazole.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Emedastine.]
[N05BA10, ketazolam, Atomoxetine may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Atomoxetine is combined with Kebuzone.]
[L01EA01, imatinib, The metabolism of Atomoxetine can be decreased when combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Levocabastine.]
[N07BC04, lofexidine, Atomoxetine may decrease the antihypertensive activities of Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Atomoxetine is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Atomoxetine is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[C09AA03, lisinopril, Atomoxetine may decrease the antihypertensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, Atomoxetine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The metabolism of Atomoxetine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Mebeverine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Atomoxetine is combined with Mefenorex.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Atomoxetine.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Mequitazine.]
[J01DH02, meropenem, Atomoxetine may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Adenosine.]
[N04AA03, methixene, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Cyclizine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The metabolism of Atomoxetine can be decreased when combined with Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Atomoxetine.]
[S01XA18, cyclosporine, The metabolism of Atomoxetine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Atomoxetine.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Atomoxetine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Atomoxetine is combined with Morniflumate.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC05, moxonidine, Atomoxetine may decrease the antihypertensive activities of Moxonidine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Vardenafil.]
[M01AH05, etoricoxib, The metabolism of Atomoxetine can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, Atomoxetine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[C02CC04, debrisoquin, Atomoxetine may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Nabilone.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Atomoxetine is combined with Nabumetone.]
[N07BB05, nalmefene, Atomoxetine may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[C07AB12, nebivolol, Atomoxetine may decrease the antihypertensive activities of Nebivolol.]
[S01GX04, nedocromil, Atomoxetine may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Atomoxetine can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Atomoxetine may decrease the antihypertensive activities of Nicorandil.]
[L02BB02, nilutamide, Atomoxetine may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Atomoxetine is combined with Theodrenaline.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Norfenefrine.]
[B01AX05, fondaparinux, Atomoxetine may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[N06AB10, escitalopram, The metabolism of Atomoxetine can be decreased when combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Olsalazine.]
[N06AA01, desipramine, The metabolism of Atomoxetine can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Atomoxetine.]
[V04CH02, indigo carmine, Atomoxetine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Atomoxetine may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[C09XA02, aliskiren, Atomoxetine may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Atomoxetine is combined with Oxaprozin.]
[N04AA08, dexetimide, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Dexetimide.]
[G04BD04, oxybutynin, The metabolism of Atomoxetine can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Atomoxetine can be decreased when combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Atomoxetine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Atomoxetine can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Amphetamine.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Atomoxetine.]
[N06AB05, paroxetine, The metabolism of Atomoxetine can be decreased when combined with Paroxetine.]
[P03AC04, permethrin, Atomoxetine may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Atomoxetine may decrease the excretion rate of Diazepam which could result in a higher serum level.]
[V03AH01, diazoxide, Atomoxetine may decrease the antihypertensive activities of Diazoxide.]
[N06AA08, dibenzepin, The risk or severity of hypertension can be increased when Atomoxetine is combined with Dibenzepin.]
[R05DA08, pholcodine, Atomoxetine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Atomoxetine is combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Foscarnet.]
[A03AA07, dicyclomine, Atomoxetine may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Atomoxetine may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[C02DG01, pinacidil, Atomoxetine may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Pinaverium.]
[A03AB14, pipenzolate, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Atomoxetine.]
[R03CC07, pirbuterol, Atomoxetine may increase the tachycardic activities of Pirbuterol.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of hypertension can be increased when Atomoxetine is combined with Diethylpropion.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Atomoxetine.]
[D07XC04, diflucortolone, Atomoxetine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Atomoxetine is combined with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Digitoxin.]
[C01AA05, digoxin, Atomoxetine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Atomoxetine may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Dihydroergotamine.]
[N02AA03, hydromorphone, Atomoxetine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, Atomoxetine may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Treprostinil.]
[H03BC01, potassium perchlorate, Atomoxetine may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Atomoxetine may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[C08DB01, diltiazem, Atomoxetine may decrease the antihypertensive activities of Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Atomoxetine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[R06AB03, dimethindene, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Dimetindene.]
[R03CC08, procaterol, Atomoxetine may increase the tachycardic activities of Procaterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Atomoxetine can be decreased when combined with Dimethyl sulfoxide.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Atomoxetine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Atomoxetine is combined with Proglumetacin.]
[R06AA02, diphenhydramine, The metabolism of Atomoxetine can be decreased when combined with Diphenhydramine.]
[C09AA06, quinapril, Atomoxetine may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Atomoxetine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Quinupramine.]
[A03FA02, cisapride, The metabolism of Atomoxetine can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Atomoxetine may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, The metabolism of Remoxipride can be decreased when combined with Atomoxetine.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Atomoxetine is combined with Reproterol.]
[S01AX06, resorcinol, Atomoxetine may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Atomoxetine can be decreased when combined with Rifamycin.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Levocetirizine.]
[N01BB09, ropivacaine, Atomoxetine may decrease the excretion rate of Ropivacaine which could result in a higher serum level.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Sunitinib.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Atomoxetine.]
[G04BE08, tadalafil, Atomoxetine may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Atomoxetine is combined with Ketorolac.]
[C02KX02, ambrisentan, Atomoxetine may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Atomoxetine can be decreased when combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Atomoxetine is combined with Salsalate.]
[R03AC12, salmeterol, Atomoxetine may increase the tachycardic activities of Salmeterol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[C01CA07, dobutamine, Atomoxetine may increase the tachycardic activities of Dobutamine.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Domperidone.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Dopamine.]
[N06AA16, dothiepin, The metabolism of Atomoxetine can be decreased when combined with Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Atomoxetine is combined with Doxapram.]
[N06AA12, doxepin, The metabolism of Atomoxetine can be decreased when combined with Doxepin.]
[L01DB01, doxorubicin, The metabolism of Atomoxetine can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Doxylamine.]
[N06AB06, sertraline, The metabolism of Atomoxetine can be decreased when combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of hypertension can be increased when Atomoxetine is combined with Droperidol.]
[A08AA10, sibutramine, Atomoxetine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Atomoxetine.]
[A12CA02, sodium sulfate, Atomoxetine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Atomoxetine may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, Atomoxetine may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Atomoxetine is combined with Sumatriptan.]
[V04CX07, edrophonium, Atomoxetine may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Temafloxacin.]
[L01AX03, temozolomide, Atomoxetine may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Atomoxetine is combined with Tenoxicam.]
[G04CA03, terazosin, Atomoxetine may decrease the antihypertensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Atomoxetine can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Terodiline.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Atomoxetine.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Atomoxetine is combined with Tetryzoline.]
[G04BD01, emepronium, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Emepronium.]
[N06AX14, tianeptine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Tianeptine.]
[C09AA02, enalapril, Atomoxetine may decrease the antihypertensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Atomoxetine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Toloxatone is combined with Atomoxetine.]
[S01AA13, fusidic acid, The metabolism of Atomoxetine can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Pipemidic acid.]
[S02BA08, fluocinolone acetonide, Atomoxetine may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Atomoxetine is combined with Mefenamic acid.]
[C01DA05, pentaerythritol tetranitrate, Atomoxetine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Atomoxetine is combined with Tramazoline.]
[C09AA10, trandolapril, Atomoxetine may decrease the antihypertensive activities of Trandolapril.]
[A03AB08, tridihexethyl, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Tridihexethyl.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Triptorelin.]
[N04AA12, tropatepine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Atomoxetine is combined with Tulobuterol.]
[C02CA06, urapidil, Atomoxetine may decrease the antihypertensive activities of Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Enoxacin.]
[L01CA04, vinorelbine, The metabolism of Atomoxetine can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Ephedrine.]
[S01GX10, epinastine, The metabolism of Atomoxetine can be decreased when combined with Epinastine.]
[N06AX16, venlafaxine, The metabolism of Atomoxetine can be decreased when combined with Venlafaxine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Atomoxetine is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Atomoxetine is combined with Xylometazoline.]
[S01EA01, epinephrine, Atomoxetine may increase the tachycardic activities of Epinephrine.]
[C09AA15, zofenopril, Atomoxetine may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Atomoxetine.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Atomoxetine is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Zonisamide.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[C02AC02, guanfacine, Atomoxetine may decrease the antihypertensive activities of Guanfacine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Moricizine.]
[G02AB03, ergonovine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of hypertension can be increased when Atomoxetine is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Ergotamine.]
[L03AX05, pidotimod, Atomoxetine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Erythromycin.]
[N05CD04, estazolam, Atomoxetine may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Atomoxetine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, Atomoxetine may decrease the excretion rate of Estradiol which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J04AK02, ethambutol, Atomoxetine may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Atomoxetine.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Gepefrine.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ibutilide.]
[N04AA05, profenamine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Profenamine.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ethosuximide.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Atomoxetine is combined with Meloxicam.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Atomoxetine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Atomoxetine is combined with Etomidate.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Atomoxetine.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Atomoxetine.]
[R06AX12, terfenadine, The metabolism of Atomoxetine can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Atomoxetine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The metabolism of Atomoxetine can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Atomoxetine can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Leuprolide.]
[M01CB01, gold sodium thiomalate, Atomoxetine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Atomoxetine may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Atomoxetine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Famotidine.]
[A16AA01, levocarnitine, Atomoxetine may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[C08CA02, felodipine, The metabolism of Atomoxetine can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Fendiline.]
[N03AX26, fenfluramine, The metabolism of Atomoxetine can be decreased when combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Atomoxetine is combined with Fenoprofen.]
[R03CC04, fenoterol, Atomoxetine may increase the tachycardic activities of Fenoterol.]
[N02AB03, fentanyl, The risk or severity of hypertension can be increased when Atomoxetine is combined with Fentanyl.]
[R03CC02, albuterol, Atomoxetine may increase the tachycardic activities of Salbutamol.]
[L01BB06, clofarabine, Atomoxetine may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[G04BD02, flavoxate, Atomoxetine may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The metabolism of Atomoxetine can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Atomoxetine.]
[J02AX01, flucytosine, Atomoxetine may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Atomoxetine may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Atomoxetine.]
[N06AA14, melitracen, The risk or severity of hypertension can be increased when Atomoxetine is combined with Melitracen.]
[L01BC09, floxuridine, Atomoxetine may decrease the excretion rate of Floxuridine which could result in a higher serum level.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Fluorouracil.]
[N06AB03, fluoxetine, The metabolism of Atomoxetine can be decreased when combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Flupentixol.]
[N05AB02, fluphenazine, The metabolism of Atomoxetine can be decreased when combined with Fluphenazine.]
[N05CD01, flurazepam, Atomoxetine may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Atomoxetine is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Fluspirilene.]
[L02BB01, flutamide, Atomoxetine may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[S02AA17, fosfomycin, Atomoxetine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[L01BC03, tegafur, Atomoxetine may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Atomoxetine is combined with Adrafinil.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Atomoxetine.]
[J05AE10, darunavir, The metabolism of Atomoxetine can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Atomoxetine may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Galantamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Gallopamil.]
[S01AD09, ganciclovir, Atomoxetine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[C10AB04, gemfibrozil, Atomoxetine may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dasatinib.]
[N04BC06, cabergoline, The risk or severity of hypertension can be increased when Cabergoline is combined with Atomoxetine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of hypertension can be increased when Atomoxetine is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Lapatinib.]
[A10BB07, glipizide, Atomoxetine may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The metabolism of Atomoxetine can be decreased when combined with Dexmedetomidine.]
[C05AE01, nitroglycerin, Atomoxetine may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dofetilide.]
[C02CA04, doxazosin, Atomoxetine may decrease the antihypertensive activities of Doxazosin.]
[L01EX02, sorafenib, The metabolism of Atomoxetine can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Atomoxetine.]
[M01CB04, aurothioglucose, Atomoxetine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Atomoxetine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Atomoxetine may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Atomoxetine may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Goserelin.]
[P01BX01, halofantrine, The metabolism of Atomoxetine can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of hypertension can be increased when Atomoxetine is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Histrelin.]
[N05AH04, quetiapine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Quetiapine.]
[N06BX13, idebenone, Atomoxetine may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[M04AA01, allopurinol, Atomoxetine may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Losartan.]
[G03DC01, allylestrenol, Atomoxetine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Atomoxetine.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[R03CC05, hexoprenaline, Atomoxetine may increase the tachycardic activities of Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Atomoxetine can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, Atomoxetine may decrease the antihypertensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Atomoxetine is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Oxatomide.]
[C09AA04, perindopril, Atomoxetine may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Atomoxetine may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Atomoxetine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[G04BD06, propiverine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Propiverine.]
[P01BA02, hydroxychloroquine, The metabolism of Atomoxetine can be decreased when combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Atomoxetine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, The metabolism of Atomoxetine can be decreased when combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Hydroxyzine.]
[C02AC06, rilmenidine, Atomoxetine may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Atomoxetine is combined with Ibuprofen.]
[B05XA08, sodium acetate, Atomoxetine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Atomoxetine.]
[L01AA06, ifosfamide, Atomoxetine may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of hypertension can be increased when Atomoxetine is combined with Sufentanil.]
[N06AA02, imipramine, The metabolism of Atomoxetine can be decreased when combined with Imipramine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Terlipressin.]
[R01AD07, tixocortol, Atomoxetine may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Tizanidine.]
[L01CE01, topotecan, Atomoxetine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Atomoxetine is combined with Indomethacin.]
[C02CA02, indoramin, Atomoxetine may decrease the antihypertensive activities of Indoramin.]
[A11HA07, inositol, Atomoxetine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Atomoxetine may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[A03AA30, piperidolate, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Piperidolate.]
[S01XA28, varenicline, Atomoxetine may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[A10BH01, sitagliptin, Atomoxetine may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, Atomoxetine may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Atomoxetine may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Buclizine.]
[C10AA06, cerivastatin, The metabolism of Atomoxetine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Anagrelide.]
[C07AA01, alprenolol, Atomoxetine may decrease the antihypertensive activities of Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Atomoxetine may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of hypertension can be increased when Atomoxetine is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Iproniazid is combined with Atomoxetine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Atomoxetine.]
[R03CC06, isoetharine, Atomoxetine may increase the tachycardic activities of Isoetharine.]
[C09AA16, imidapril, Atomoxetine may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Isoflurane.]
[N04BX02, entacapone, The metabolism of Atomoxetine can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Atomoxetine can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Atomoxetine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, Atomoxetine may increase the tachycardic activities of Isoprenaline.]
[D10BA01, isotretinoin, Atomoxetine may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Isoxsuprine.]
[N06AX18, reboxetine, The metabolism of Atomoxetine can be decreased when combined with Reboxetine.]
[S01AA24, kanamycin, Atomoxetine may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Atomoxetine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Atomoxetine may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, Atomoxetine may decrease the antihypertensive activities of Ketanserin.]
[B01AC22, prasugrel, Atomoxetine may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Atomoxetine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Atomoxetine is combined with Ketoprofen.]
[L04AA24, abatacept, The metabolism of Atomoxetine can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Mizolastine.]
[C01CA22, arbutamine, Atomoxetine may increase the tachycardic activities of Arbutamine.]
[N04BC09, rotigotine, The metabolism of Atomoxetine can be decreased when combined with Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Nalidixic acid.]
[C07AG01, labetalol, The metabolism of Atomoxetine can be decreased when combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Amantadine.]
[C02AA05, deserpidine, Atomoxetine may decrease the antihypertensive activities of Deserpidine.]
[A06AX03, lubiprostone, Atomoxetine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[S02DA01, lidocaine, The metabolism of Atomoxetine can be decreased when combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Lidoflazine.]
[S01AA21, amikacin, Atomoxetine may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The risk or severity of hypertension can be increased when Atomoxetine is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Lofepramine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Loperamide.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[C10AA02, lovastatin, The metabolism of Atomoxetine can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The metabolism of Atomoxetine can be decreased when combined with Temsirolimus.]
[B05XA11, magnesium chloride, Atomoxetine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Atomoxetine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[L01BA05, pralatrexate, Atomoxetine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Maprotiline.]
[C02BB01, mecamylamine, Atomoxetine may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The metabolism of Meclizine can be decreased when combined with Atomoxetine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Atomoxetine is combined with Meclofenamic acid.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Mefloquine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DX01, memantine, Atomoxetine may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Atomoxetine may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Mephentermine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Atomoxetine.]
[N01BB03, mepivacaine, Atomoxetine may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[G04BX16, tiopronin, Atomoxetine may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Atomoxetine is combined with Metaraminol.]
[A10BA02, metformin, Atomoxetine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dolasetron.]
[N07BC02, methadone, The metabolism of Atomoxetine can be decreased when combined with Methadone.]
[N06BA03, methamphetamine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Metamfetamine.]
[A03AB07, methantheline, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Methantheline.]
[J05AF05, lamivudine, Atomoxetine may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, The risk or severity of hypertension can be increased when Atomoxetine is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Atomoxetine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Atomoxetine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N05AA02, methotrimeprazine, The metabolism of Atomoxetine can be decreased when combined with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Methoxamine.]
[D05BA02, methoxsalen, Atomoxetine may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of hypertension can be increased when Atomoxetine is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Atomoxetine may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Methylene blue is combined with Atomoxetine.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Methylergometrine.]
[G03EK01, methyltestosterone, Atomoxetine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N02CA04, methysergide, The risk or severity of hypertension can be increased when Methysergide is combined with Atomoxetine.]
[A03FA01, metoclopramide, The metabolism of Atomoxetine can be decreased when combined with Metoclopramide.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The metabolism of Atomoxetine can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Metronidazole.]
[V04CD01, metyrapone, Atomoxetine may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Atomoxetine.]
[N06AX03, mianserin, The risk or severity of hypertension can be increased when Atomoxetine is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Atomoxetine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Aminophenazone.]
[N05CD08, midazolam, Atomoxetine may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Midodrine.]
[G03XB01, mifepristone, The metabolism of Atomoxetine can be decreased when combined with Mifepristone.]
[J05AH01, zanamivir, Atomoxetine may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, Atomoxetine may decrease the antihypertensive activities of Valsartan.]
[D11AX01, minoxidil, Atomoxetine may decrease the antihypertensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, The metabolism of Atomoxetine can be decreased when combined with Lisdexamfetamine.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Atomoxetine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Atomoxetine can be decreased when combined with Amitriptyline.]
[A04AA05, palonosetron, Atomoxetine may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Atomoxetine can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, Atomoxetine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Pazopanib.]
[L04AA06, mycophenolic acid, Atomoxetine may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[P01BA06, amodiaquine, The metabolism of Atomoxetine can be decreased when combined with Amodiaquine.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Atomoxetine.]
[C07AA12, nadolol, Atomoxetine may decrease the antihypertensive activities of Nadolol.]
[J01CA04, amoxicillin, Atomoxetine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, Atomoxetine may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[L04AC03, anakinra, The metabolism of Atomoxetine can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Atomoxetine is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Amphetamine.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Atomoxetine is combined with Naproxen.]
[N06AX21, duloxetine, The metabolism of Atomoxetine can be decreased when combined with Duloxetine.]
[N04BX01, tolcapone, Atomoxetine may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[S03AA01, neomycin, Atomoxetine may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Atomoxetine is combined with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Levosimendan.]
[B01AC17, tirofiban, Atomoxetine may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[S01AA19, ampicillin, Atomoxetine may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Atomoxetine may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Atomoxetine may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Atomoxetine may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[C09CA07, telmisartan, Atomoxetine may decrease the antihypertensive activities of Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[C01CE01, inamrinone, Atomoxetine may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The metabolism of Atomoxetine can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Nialamide is combined with Atomoxetine.]
[C08CA04, nicardipine, The metabolism of Atomoxetine can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Atomoxetine is combined with Nicergoline.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Atomoxetine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Atomoxetine is combined with Niflumic acid.]
[C08CA06, nimodipine, Atomoxetine may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Atomoxetine may decrease the antihypertensive activities of Nisoldipine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Nitrendipine.]
[R07AX01, nitric oxide, Atomoxetine may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Atomoxetine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, Atomoxetine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BC05, pramipexole, Atomoxetine may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Atomoxetine may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of hypertension can be increased when Atomoxetine is combined with Nitrous oxide.]
[C01CA03, norepinephrine, Atomoxetine may increase the tachycardic activities of Norepinephrine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Norfloxacin.]
[C02KX01, bosentan, Atomoxetine may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, The metabolism of Atomoxetine can be decreased when combined with Nortriptyline.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Atomoxetine is combined with Nylidrin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atomoxetine.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Atomoxetine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Atomoxetine can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of hypertension can be increased when Atomoxetine is combined with Opipramol.]
[N02AA02, opium, Atomoxetine may decrease the excretion rate of Opium which could result in a higher serum level.]
[R03CB03, metaproterenol, Atomoxetine may increase the tachycardic activities of Orciprenaline.]
[G04CA02, tamsulosin, Atomoxetine may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[J01CF04, oxacillin, Atomoxetine may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[P02BA02, oxamniquine, The metabolism of Atomoxetine can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, Atomoxetine may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The metabolism of Atomoxetine can be decreased when combined with Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be decreased when combined with Atomoxetine.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Atomoxetine is combined with Oxymetazoline.]
[A14AA05, oxymetholone, The metabolism of Atomoxetine can be decreased when combined with Oxymetholone.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Atomoxetine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Atomoxetine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Atomoxetine.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atomoxetine.]
[N05AH05, asenapine, The metabolism of Atomoxetine can be decreased when combined with Asenapine.]
[M03AC01, pancuronium, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Pancuronium.]
[J04AB30, capreomycin, Atomoxetine may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Papaverine.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Pargyline is combined with Atomoxetine.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Pefloxacin.]
[G04BD11, fesoterodine, Atomoxetine may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Atomoxetine may decrease the antihypertensive activities of Penbutolol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Atomoxetine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Atomoxetine may decrease the excretion rate of Pentobarbital which could result in a higher serum level.]
[L01XX08, pentostatin, Atomoxetine may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Atomoxetine may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[N04BC02, pergolide, The risk or severity of hypertension can be increased when Atomoxetine is combined with Pergolide.]
[C08EX02, perhexiline, The metabolism of Atomoxetine can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The metabolism of Atomoxetine can be decreased when combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Atomoxetine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Atomoxetine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Atomoxetine.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Pheniramine.]
[C04AX02, phenoxybenzamine, Atomoxetine may decrease the antihypertensive activities of Phenoxybenzamine.]
[A08AA01, phentermine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Phentermine.]
[V03AB36, phentolamine, Atomoxetine may decrease the antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Atomoxetine is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Phenylephrine.]
[R01BA01, phenylpropanolamine, Atomoxetine may increase the tachycardic activities of Phenylpropanolamine.]
[N03AB02, phenytoin, The metabolism of Atomoxetine can be decreased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Atomoxetine can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Atomoxetine can be decreased when combined with Bicalutamide.]
[B02BA01, vitamin K1, Atomoxetine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[C08CX01, mibefradil, The metabolism of Atomoxetine can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Atomoxetine can be decreased when combined with Pimozide.]
[C07AA03, pindolol, The metabolism of Atomoxetine can be decreased when combined with Pindolol.]
[J01CA12, piperacillin, Atomoxetine may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Atomoxetine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Atomoxetine.]
[N05AC04, pipothiazine, The metabolism of Atomoxetine can be decreased when combined with Pipotiazine.]
[N06BX03, piracetam, Atomoxetine may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, Atomoxetine may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Pirenzepine.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Atomoxetine is combined with Piroxicam.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Grepafloxacin.]
[N02CX01, pizotyline, The risk or severity of hypertension can be increased when Atomoxetine is combined with Pizotifen.]
[J05AG02, delavirdine, The metabolism of Atomoxetine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Atomoxetine may decrease the antihypertensive activities of Irbesartan.]
[A10BG02, rosiglitazone, The metabolism of Atomoxetine can be decreased when combined with Rosiglitazone.]
[L04AC08, canakinumab, The metabolism of Atomoxetine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The metabolism of Atomoxetine can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, Atomoxetine may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Atomoxetine may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[C07AB01, practolol, Atomoxetine may decrease the antihypertensive activities of Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Prajmaline.]
[C02CA01, prazosin, Atomoxetine may decrease the antihypertensive activities of Prazosin.]
[H02AB07, prednisone, Atomoxetine may decrease the excretion rate of Prednisone which could result in a higher serum level.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Prenylamine.]
[P01BA03, primaquine, The metabolism of Atomoxetine can be decreased when combined with Primaquine.]
[M04AB01, probenecid, Atomoxetine may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Probucol.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Atomoxetine.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Atomoxetine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Atomoxetine.]
[C10AB05, fenofibrate, Atomoxetine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Prochlorperazine.]
[N04AA04, procyclidine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Atomoxetine.]
[N05AA03, promazine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Promazine.]
[R06AD02, promethazine, The metabolism of Atomoxetine can be decreased when combined with Promethazine.]
[C01BC03, propafenone, The metabolism of Atomoxetine can be decreased when combined with Propafenone.]
[A03AB05, propantheline, Atomoxetine may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[N05AC01, periciazine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Periciazine.]
[N05CM06, propiomazine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Atomoxetine can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Atomoxetine can be decreased when combined with Propranolol.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Atomoxetine is combined with Rizatriptan.]
[B01AC09, epoprostenol, Atomoxetine may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Protriptyline.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Aripiprazole.]
[N07XX07, dalfampridine, Atomoxetine may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[A03AB15, diphemanil, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Isopropamide.]
[S01FA03, methscopolamine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Methscopolamine.]
[P02CC01, pyrantel, Atomoxetine may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Atomoxetine may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[R06AC01, pyrilamine, The metabolism of Atomoxetine can be decreased when combined with Mepyramine.]
[C01BA01, quinidine, The metabolism of Atomoxetine can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Atomoxetine can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Atomoxetine can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, Atomoxetine may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, Atomoxetine may decrease the antihypertensive activities of Reserpine.]
[J05AP01, ribavirin, Atomoxetine may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Atomoxetine is combined with Rimiterol.]
[G02CA01, ritodrine, Atomoxetine may increase the tachycardic activities of Ritodrine.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Atomoxetine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Atomoxetine is combined with Salicylic acid.]
[S01FA02, scopolamine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Scopolamine.]
[N05CA06, secobarbital, Atomoxetine may decrease the excretion rate of Secobarbital which could result in a higher serum level.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Atomoxetine.]
[J01GB08, sisomicin, Atomoxetine may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Atomoxetine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Atomoxetine may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Atomoxetine.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Atomoxetine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Valproic acid.]
[C01DA14, isosorbide mononitrate, Atomoxetine may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10AX03, azelaic acid, Atomoxetine may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Atomoxetine is combined with Tiaprofenic acid.]
[R03BB01, ipratropium bromide, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Ipratropium.]
[N06AF04, tranylcypromine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06AF01, isocarboxazid, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06AF03, phenelzine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[L01XB01, procarbazine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N04BD01, selegiline, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
